Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

Bladé, J., Samson, D., Reece, D. E., Apperley, J. F., Björkstrand, B., Gahrton, G., Gertz, M. A., Giralt, S. A., Jagannath, S., & Vesole, D. H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,516

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

Hideshima, T., Chauhan, D., Shima, Y., Raje, N. S., Davies, F. E., Tai, Y., Treon, S. P., Lin, B. K., Schlossman, R. L., Richardson, P. G. G., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 874

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

Palumbo, A. P., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G. G., Miguel, J. F. S., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Miguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 806

Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α

Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 792

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721

The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma

Comeau, J. M., Kelly, K., & Jean, G. W. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160554 · Cited by 2

Current Treatment Approaches to Multiple Myeloma with New Agents

Maral, S., Albayrak, M., & Pala, Ç. (2018) · Journal of Clinical and Experimental Investigations · doi:10.5799/jcei.433823 · Cited by 2

Myeloma clinical outcomes following the first wave of COVID‐19: results from the Thames Valley Cancer Alliance (UK)

Sharpley, F. A., Larham, J., Haines, A., Djebbari, F., Tseu, B., Leary, H., Vallance, G. D., Panitsas, F. P., Ferguson, L., Roberts, P. J., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17261 · Cited by 2

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils

Romano, A., Parrinello, N. L., Parisi, M. S., Fabro, V. D., Curtopelle, A., Leotta, S., Conticello, C., & Raimondo, F. D. (2021) · Biomedicines · doi:10.3390/biomedicines9101455 · Cited by 2

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

Bhutani, D., & Zonder, J. A. (2017) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s82444 · Cited by 2

Current and future perspectives of maintenance therapy in multiple myeloma

Nagarajan, C., Tan, M. S. Y., Chen, Y., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04117-8 · Cited by 2

Pomalidomide improves the function of CD133- or HER2-specific CAR T cells

Wang, Z., Na, R., Fu, J., Liu, H., ZHOU, G., Liu, Q., Zou, Y., Tang, J., Li, L., & Zhu, X. (2021) · Biocell · doi:10.32604/biocell.2021.010261 · Cited by 2

Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data

Sandecká, V., Pour, L., Špıčka, I., Minařík, J., Radocha, J., Jelı́nek, T., Pavlíček, P., Jungová, A., Kessler, P., Wróbel, M., et al. (2022) · Neoplasma · doi:10.4149/neo_2022_220813n827 · Cited by 2

Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis

Rose, C. J., Ohm, I. K., Giske, L. E., Næss, G. E., & Fretheim, A. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-067966 · Cited by 2

Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial

Zhou, H., Wang, Y., Chen, J., He, A., Jin, J., Lu, Q., Zhao, Y., Li, J., Hou, M., Su, L., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05558-y · Cited by 2

Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes

Faiman, B. M., & Valent, J. N. (2016) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s90764 · Cited by 3

Pomalidomide dans les myélomes multiples

Dougé, A., Lemal, R., & Chaleteix, C. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.04.005 · Cited by 2

A look at treatment strategies for relapsed multiple myeloma

Cetani, G., Boccadoro, M., & Oliva, S. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1477594 · Cited by 2

Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity

Yu, T., Qiao, C., Lv, M., & Tang, L. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0524-8 · Cited by 2

Treatment Approaches of Multiple Myeloma

Woldu, M. A., Fentie, A. M., & Tadesse, T. A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97390 · Cited by 2

Innovations in treatment and response evaluation in multiple myeloma

Wester, R., & Sonneveld, P. (2016) · Haematologica · doi:10.3324/haematol.2016.142737 · Cited by 2

Principles of prevention and management of adverse events of immunomodulatory drugs in the treatment of multiple myeloma

Charliński, G., Vesole, D. H., & Jurczyszyn, A. J. (2022) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2022.0031 · Cited by 1

Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis

Luo, Y., Li, C., Niu, Y., Wu, S., Tian, J., Hu, Z., He, J., Zhang, Z., Liu, H., Li, Y., et al. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2326219 · Cited by 1

Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen

Whiteley, A., Ijioma, S. C., Ray, D., Langerman, S. S., Hu, E., Pierre, A. E., Mark, T. M., & Yimer, H. A. (2025) · Current Oncology · doi:10.3390/curroncol32050268 · Cited by 2

Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study

Burnett, J., Sychterz, C. J., Katz, J. B., Shakeel, F., Silva, J., Chen, W., Shahane, A., Wang, X., Lamba, M., & Gaudy, A. M. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70082 · Cited by 1

Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline

Jenner, M. W., Boyd, K. D., Choudhuri, S., Parrish, C., Garg, M. K., Stern, S., & the British Society of Haematology and UK Myeloma Society (2025) · British Journal of Haematology · doi:10.1111/bjh.70149 · Cited by 2

Pomalidomide re-exposure after drug-related severe hypothyroidism: a case report

Bartolomei, F., Za, T., Landro, F. D., Stefano, V. D., & Rossi, E. G. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06904-6 · Cited by 1

Pomalidomide for the treatment of relapsed and refractory multiple myeloma

Guidetti, A., Prada, C. P., Laubach, J. P., Varga, C., Maglio, M. E., McKenney, M., Doss, D. S., Schlossman, R. L., Mitsiades, C. S., Hideshima, T., et al. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.953480 · Cited by 1

Pomalidomide for Treatment of Relapsed and Refractory Multiple Myeloma

Семочкин, С. В. (2015) · Clinical oncohematology · doi:10.21320/2500-2139-2015-8-4-379-389 · Cited by 1

Pomalidomide (Pomalyst® capsule 1 mg/2 mg/3 mg/4 mg): pharmacokinetics, pharmacodynamics and clinical study outcome

Torigoe, K., Nakayama, N., & Achiwa, H. (2016) · Folia Pharmacologica Japonica · doi:10.1254/fpj.148.154 · Cited by 1

Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma

Salvini, M., Bonello, F., Boccadoro, M., & Larocca, A. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1266264 · Cited by 1

Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma

Petričević, B., Hilbe, W., & Zojer, N. (2017) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-017-0342-4 · Cited by 1

Treatment of Patients in First or Second Relapse

Yee, A. J., & Raje, N. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-61872-2_5 · Cited by 1

Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data

Li, S., Meng, X., Maman, S. T. D., Xiao, Y.-N., & Li, S. (2018) · BioMed Research International · doi:10.1155/2018/9057823 · Cited by 1

Real-world Data-based Adverse Drug Reactions Analysis of Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Ko, M., Choi, J., Kim, S., Kim, S. H., Cho, E., Cho, Y. S., Koh, Y. I., & Oh, J. M. (2022) · Journal of Pharmacoepidemiology and Risk Management · doi:10.56142/jperm.22.0014 · Cited by 1

Restoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature

Biran, N., Vesole, D. H., Parmar, H. V., Phull, P. M., Kumka, S., Doucette, K., Zenreich, J., DeAgresta, B., Pia, A. D., Biamonte, L., et al. (2024) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2024.100336 · Cited by 1

A Journey Through the Golden Era of Myeloma Treatment: From Bench to Bedside

Jagannath, S. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.12.003 · Cited by 1

Pomalidomide – An Appraisal of Its Clinical Development and Role in the Treatment of Relapsed/Refractory Multiple Myeloma

Richardson, P. G. G., Palumbo, A. P., Schey, S., Dimopoulos, M. A., Facon, T. T. F., Weisel, K. C., O’Gorman, P., Leleu, X. P., Lacy, M. Q., Streetly, M. J., et al. (2015) · European Oncology & Haematology · doi:10.17925/eoh.2015.11.02.109 · Cited by 1

The “Next Big Thing” in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design—Between the Lines

Ruggeri, K., Maguire, Á., & Cook, G. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1782 · Cited by 1

Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?

Kalis, J. A. (2017) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2017.8.1.7 · Cited by 1

Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma

Petrov, A. V., Васильевич, М. Д., Pokrovskaya, O. S., Urnova, E. S., Нарейко, М. В., Babenetskaya, D., Alekseeva, Y. A., Гиршова, Л. Л., Mendeleeva, L. P., & Zaritskii, A. Y. (2017) · Clinical oncohematology · doi:10.21320/2500-2139-2017-10-3-372-380 · Cited by 1

A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma

Dinner, S. N., Dunn, T. J., Price, E. A., Coutre, S. E., Gotlib, J. R., Berube, C., Kaufman, G. P., Medeiros, B. C., & Liedtke, M. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2468-5 · Cited by 1

Pomalidomide and dexamethasone in myelomatous pleural effusion

Comba, I. Y., Chahin, A., Taj, H., & Carilli, A. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-235899 · Cited by 1

Rapid Review on Multiple Myeloma; Current Clinical Management

Khazeni, S., & Bigdeli, B. (2022) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2022.06.0843

A new treatment option for relapsed and refractory MM

(2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.11 · Cited by 1

Pomalidomide

Yeung, A. J.-T., & Ling, S. (2021) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-73440-4_3 · Cited by 1

Synthesis and Anti-Tumor Effects of Novel Pomalidomide Derivatives Containing Urea Moieties

Guo, Y., Wang, X., Wang, Z., Mao, L., Wang, J., Peng, L., & Xu, G. (2022) · Pharmaceuticals · doi:10.3390/ph15121479 · Cited by 1

Multiple Myeloma

Bianchi, G., & Anderson, K. C. (2015) · Wiley eBooks · doi:10.1002/9781118468678.ch14 · Cited by 1

Personalized genotyping!based therapy

Chuchalin, A. G. (2014) · PULMONOLOGIYA · doi:10.18093/0869-0189-2014-0-4-5-12

Biological markers and treatment as prognostic factors in multiple myeloma

Uttervall, K. (2015) · Figshare

Pomalidomide in the Treatment of Multiple Myeloma and Perspectives in other Hematological Malignancies

Oriol, A. (2014) · International Journal of Hematologic Oncology · doi:10.2217/ijh.14.16

Novel Agents for Treatment of Multiple Myeloma

Kim, H. J. (2015) · Korean Journal of Medicine · doi:10.3904/kjm.2015.88.3.252

Cereblon and Its Role in the Treatment of Multiple Myeloma by Lenalidomide or Pomalidomide

Fuchs, O., Bokorová, R., Vostrý, M., Kostečka, A., & Poläk, J. (2014) · doi:10.12691/ijhd-1-1a-3

Clinical and Population-based Studies in Multiple Myeloma and Monoclonal Gammopathy – Focus on Infections

Blimark, C. H. (2014) · Gothenburg University Publications Electronic Archive (Gothenburg University)

Is Pomalidomide Plus Low Dose Dexamethasone an Effective and Safe Treatment for Patients With Relapsed or Refractory Multiple Myeloma

Westervelt, M. (2015) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)

Szpiczak plazmocytowy — praktyczne aspekty dotyczące diagnostyki i leczenia

Charliński, G., & Wiater, E. (2014)

Pomalidomide: when Expectations are Understated

Raimondo, F. D., & Conticello, C. (2017) · Future Oncology · doi:10.2217/fon-2016-0559

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma

Fouquet, G., Karlin, L., Macro, M., Caillot, D., Roussel, M., Arnulf, B., Pegourié, B., Petillon, M. O., Mathiot, C., Hulin, C., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3236-6

Next-generation immunomodulatory drugs in multiple myeloma

Suska, A., Czerniuk, M. R., & Jurczyszyn, A. J. (2019) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0013.6907

Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple MyelomaPreprint

Mitsiades, C. S. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034900

Skuteczność terapii pomalidomidem u pacjenta ze szpiczakiem plazmocytowym opornym na inne leki immunomodulujące

Masternak, M., & Morawska, M. (2021) · Hematologia · doi:10.5603/hem.2020.0043

Die revolte der funfzigjahrigen / Edmund Bergler

Bergler, E. (1955)

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trialPreprint

Lu, J., Fu, W., Wang, Y.-F., Zhao, H., Niu, T., Fang, B.-J., Liao, A., & Bai, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1178265/v1

Myeloma and Leukemia

Nassar, S., Kaufman, G. P., Taher, A., Madewell, J. E., & Mujtaba, B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-69538-1.00029-x

Myeloma

Tantravahi, S. K., & Kovacsovics, T. J. (2015) · Springer eBooks · doi:10.1007/978-1-4614-5662-9_9

Cancers of the Blood

De, S. K. (2022) · Wiley eBooks · doi:10.1002/9783527838561.ch4

Effect modification in network meta-analyses of treatments for relapsing refractory multiple myeloma (RRMM): systematic review, meta-analysis, and simulationPreprint

Rose, C. J., Ohm, I. K., Giske, L. E., Næss, G. E., & Fretheim, A. (2022) · medRxiv · doi:10.1101/2022.05.13.22275047

PRACTICAL ASPECTS OF THERAPY FOR DOUBLE REFRACTORY MULTIPLE MYELOMA

Лунин, В. В. (2022) · Международная Звенигородская конференция по физике плазмы и управляемому термоядерному синтезу · doi:10.37539/vt198.2022.83.32.010

Oral Therapies for Multiple Myeloma

Singhal, S., & Kumar, S. K. (2022) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2022.18.2.139

Помалидомид в терапии рецидивирующей/рефрактерной множественной миеломы

Семочкин, С. В. (2023) · Journal of Modern Oncology · doi:10.26442/18151434.2023.2.202255

Panorama actualizado en mieloma m�ltiple

Álvarez-Vera, J. L., Alvarado‐Ibarra, M., de la Peña-Celaya, J. A., Hernández-Ruiz, E., Arana-Luna, L. L., Montoya-Jiménez, L., Espitia-Ríos, M. E., Mena, C. P., Peñaloza-Ramírez, R., & Pérez-Zúñiga, J. M. (2023) · Revista de especialidades m�dico-quir�rgicas · doi:10.24875/remq.m23000008

Multiple myeloma complicated with light chain cast nephropathy with focal amyloidosis: A case report

He, Y., Hua, Z., Tan, H., Zhao, C., Liu, Q., Jia, J., & Gao, Y. (2024) · Nephrology · doi:10.1111/nep.14315

A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death–Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma

Kourelis, T., Ailawadhi, S., Vogl, D. T., Gibson, S. E., Sharik, M. E., Du, M. T., Ames, T. D., Yim, C. Y., Baeck, J., Price, M. R., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2574

Angiogenesis in Multiple Myeloma: 25 Years of Research in This Field

Ribatti, D. (2025) · European Journal Of Haematology · doi:10.1111/ejh.70023 · Cited by 1

Additional file 1 of Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14303001

Additional file 3 of Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial

Du, J., Wang, Y., Zhao, H.-G., Niu, T., Fang, B.-J., Liao, A., Bai, H., & Lu, J. (2022) · Figshare · doi:10.6084/m9.figshare.20218380

Additional file 2 of Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14303004

Additional file 3 of Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14303007

Additional file 1 of Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial

Du, J., Wang, Y.-F., Zhao, H.-G., Niu, T., Fang, B.-J., Liao, A., Bai, H., & Lu, J. (2022) · Figshare · doi:10.6084/m9.figshare.20218374

Additional file 2 of Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial

Du, J., Wang, Y.-F., Zhao, H.-G., Niu, T., Fang, B.-J., Liao, A., Bai, H., & Lu, J. (2022) · Figshare · doi:10.6084/m9.figshare.20218377

Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China

Jiang, W. W., Zhong, W., Yu, J., 唐宇飛, & Guo, Q. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1687341

Evolution of real-world frontline treatment patterns in multiple myeloma

Lazzaro, A., Nannini, K., Yildirim, C., Huhmann, L., Culnan, J., Corrigan, J. K., Elbers, D. C., Do, N., Brophy, M. T., Munshi, N. C., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019843

Multiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management

Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 3

Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making

Bazarbachi, A. H., Lentzsch, S., Facon, T. T. F., Harousseau, J., & Mohty, M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00545

Primum non nocere: a critical analysis of early intervention clinical trials in smoldering multiple myeloma

Parmar, H. V., Biran, N., Phull, P. M., Doucette, K. R., Palma-Grisi, J. D., Franz, J., Vesole, D. H., & Siegel, D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1834686

Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results

Richardson, P. G. G., Siegel, D. S. D., Vij, R., Hofmeister, C. C., Jagannath, S., Chen, C. I., Lonial, S., Jakubowiak, A. J., Bahlis, N. J., Baz, R., et al. (2011) · Blood · doi:10.1182/blood.v118.21.634.634 · Cited by 34

A new treatment option for relapsed and refractory MM

(2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.11 · Cited by 1

Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.

Siegel, D. S. D., Richardson, P. G. G., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C. I., Lonial, S., Jakubowiak, A. J., Bahlis, N. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8588 · Cited by 7

Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).

Berenson, J. R., Stampleman, L. V., Bessudo, A., Rosen, P. J., Klein, L. M., Woliver, T. B. S., Flam, M. S., Eshaghian, S., Nassir, Y., Swift, R. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8591 · Cited by 2

A phase 1/2 study of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).

Berenson, J. R., Klein, L. M., Rosen, P. J., Woliver, T. B. S., Eshaghian, S., Nassir, Y., Swift, R. A., & Vescio, R. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.e19586 · Cited by 1